28 May 2015 07:00
News Release
28 May 2015
Consort Medical Notice of Results
Hemel Hempstead, UK, May 28, 2015 - Consort Medical plc (LSE: CSRT) ("Consort", "Consort Medical" or the "Group"), a leading, global single source drug and delivery company, will announce its full year results for the year ended 30 April 2015 on Tuesday, 16 June 2015.
-Ends-
Enquiries:
Consort Medical Jonathan Glenn - Chief Executive Officer Richard Cotton - Chief Financial Officer | Tel: +44 1442 867920 |
FTI Consulting Ben Atwell / Simon Conway | Tel: +44 20 3727 1000
|
Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.
Our businesses
Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.
Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.
We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). To learn more about our company visit our website at www.consortmedical.com.